Hormonal
Saturated fats do not cause cardiovascular disease; instead, coronary heart disease is driven by silent inflammation resulting from insufficient omega-3s, excessive omega-6s, and high fructose intake.
Stop fearing natural saturated fats like those in butter and meat. Instead, focus on reducing processed foods, sugar (especially fructose), and industrial trans fats. Ensure you get enough omega-3s from fish or supplements to manage inflammation, as this is the true driver of heart disease, not the saturated fat itself.
The data appear to be clear: the consumption of saturated fats is not responsible for cardiovascular disease [56, 57].
Why this rating
The paper cites observational studies and biochemical mechanisms but acknowledges that correlations do not equal causation and notes industry influence.
Source
Fatty acids: facts vs. fiction
Reinhard Waehler · International Journal for Vitamin and Nutrition Research · 2021
DOI 10.1024/0300-9831/a000713
More from this paper
- Industrial trans fats are harmful and should be avoided, while natural trans fats (from ruminants) are beneficial and may protect against heart disease.Good
- Flaxseed oil (ALA) is an inefficient source of EPA and DHA due to low conversion rates, making direct supplementation with long-chain omega-3s (fish oil) necessary for most people.Good
- Palmitic acid is only harmful when produced endogenously via de novo lipogenesis from excess fructose; dietary palmitic acid is not the primary culprit for metabolic issues.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →